REG - Roquefort Theraptcs. - Result of AGM

Roquefort TherapeuticsAnnouncement

30/06/2022 10:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220630:nRSd8190Qa&default-theme=true

RNS Number : 8190Q  Roquefort Therapeutics PLC  30 June 2022

30 June 2022

 

 

Roquefort Therapeutics plc

("Roquefort Therapeutics" or the "Company")

 

Results of AGM

 

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company
focused on early-stage opportunities in the biotechnology sector, is pleased
to announce that at the Company's Annual General Meeting ("AGM") held earlier
today, all resolutions proposed were duly passed.

 

The resolutions were put to shareholders via a poll, the results of which were
as follows:

 

 Resolution      Poll Results
         For     Against     Abstain  Discretionary  Total
 1       Shares  15,398,450  -        -              1,600,000  16,998,450
         %       90.59%      -        -              9.41%      100%
 2       Shares  15,398,450  -        -              1,600,000  16,998,450
         %       90.59%      -        -              9.41%      100%
 3       Shares  15,398,450  -        -              1,600,000  16,998,450
         %       90.59%      -        -              9.41%      100%
 4       Shares  15,398,450  -        -              1,600,000  16,998,450
         %       90.59%      -        -              9.41%      100%
 5       Shares  15,363,384  35,066   -              1,600,000  16,998,450
         %       90.38%      0.21%    -              9.41%      100%
 6       Shares  15,398,450  -        -              1,600,000  16,998,450
         %       90.59%      -        -              9.41%      100%
 7       Shares  15,398,450  -        -              1,600,000  16,998,450
         %       90.59%      -        -              9.41%      100%
 8       Shares  15,398,450  -        -              1,600,000  16,998,450
         %       90.59%      -        -              9.41%      100%
 9       Shares  15,363,384  35,066   -              1,600,000  16,998,450
         %       90.38%      0.21%    -              9.41%      100%
 10      Shares  15,363,384  35,066   -              1,600,000  16,998,450
         %       90.38%      0.21%    -              9.41%      100%

 

The total number of ordinary shares in issue on 28 June 2022, the deadline for
casting votes by proxy in advance of the AGM, was 71,900,000 shares.  23.64%
of voting capital was instructed in respect of the resolutions put to the AGM.

 
Enquiries:

 

 Roquefort Therapeutics plc
 Stephen West (Chairman)                    +44 (0)20 3290 9339

 Buchanan (Public Relations)

 Ben Romney / Jamie Hooper / George Beale   +44 (0)20 7466 5000

 Optiva Securities Limited (Broker)
 Christian Dennis                           +44 (0)20 3411 1881

 

For further information on Roquefort Therapeutics, please visit
www.roquefortplc.com (http://www.roquefortplc.com) and @RoquefortTherap on
Twitter.

 

LEI: ‎254900P4SISIWOR9RH34

 

About Roquefort Therapeutics

 

Roquefort Therapeutics (LSE:ROQ) is a Main Market listed biotech company
developing products through the pre-clinical phase prior to partnering or
selling to big pharma. The Company is a pre-clinical biotech company focused
on developing first in class Midkine targeting drugs for the treatment of
cancer.

 

Through extensive research resulting in validation through publication in over
1,000 scientific journals, Roquefort Therapeutics has identified the potential
to exploit the broad therapeutic potential of Midkine for a number of clinical
indications of unmet needs. Roquefort Therapeutics holds an exclusive licence
to the largest global IP portfolio on Midkine. The Midkine blocking drug
development markets have significant global market potential (in the
multi-billion dollars). Roquefort Therapeutic's pre-clinical program is
currently underway with an initial focus on cancer.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGSDDSUSEESEFM